Kymera Therapeutics Inc. (NASDAQ:KYMR) saw its stock jump 37.3% in premarket trading after the company announced strong Phase 1 trial results for KT-621, its oral STAT6 degrader targeting allergic and inflammatory diseases.
The trial demonstrated that KT-621 achieved over 90% average STAT6 degradation in blood at doses above 1.5 mg and complete degradation in both blood and skin at multiple ascending dose (MAD) levels of 50 mg or higher. These results exceeded Kymera’s internal benchmarks and significantly de-risk the program, according to management.
Importantly, KT-621 exhibited a favorable safety profile with no serious adverse events and no treatment-related side effects reported in more than one participant. The treatment’s effect on Th2 inflammatory biomarkers was described as comparable to or better than dupilumab, a leading injectable therapy in the same class.
CEO Dr. Nello Mainolfi highlighted KT-621’s potential to deliver biologic-like efficacy in an oral formulation, marking a major step forward for patients who currently rely on injections.
The double-blind, placebo-controlled Phase 1 study involved 118 healthy volunteers and showed rapid drug absorption and dose-proportional increases in exposure. These pharmacokinetic and pharmacodynamic results support continued clinical development.
Kymera is now recruiting patients for its Phase 1b BroADen trial in moderate-to-severe atopic dermatitis, with data expected in Q4 2025. Two additional Phase 2b studies – one in atopic dermatitis and another in asthma – are scheduled to begin in Q4 2025 and Q1 2026, respectively.
The market’s enthusiastic response reflects investor confidence in KT-621’s potential to disrupt the allergy and inflammation treatment landscape with a more convenient, oral alternative to existing therapies.